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ABSTRACT
Objectives To examine service provision in 
cardiovascular magnetic resonance (CMR) in the UK. 
Equitable access to diagnostic imaging is important in 
healthcare. CMR is widely available in the UK, but there 
may be regional variations.
Methods An electronic survey was sent by the British 
Society of CMR to the service leads of all CMR units in 
the UK in 2019 requesting data from 2017 and 2018. 
Responses were analysed by region and interpreted 
alongside population statistics.
Results The survey response rate was 100% (82 
units). 100 386 clinical scans were performed in 2017 
and 114 967 in 2018 (15% 1- year increase; 5- fold 
10- year increase compared with 2008 data). In 2018, 
there were 1731 CMR scans/million population overall, 
with significant regional variation, for example, 4256 
scans/million in London vs 396 scans/million in Wales. 
Median number of clinical scans per unit was 780, 
IQR 373–1951, range 98–10 000, with wide variation 
in mean waiting times (median 41 days, IQR 30–49, 
range 5–180); median 25 days in London vs 180 days 
in Northern Ireland). Twenty- five units (30%) reported 
mean elective waiting times in excess of 6 weeks, and 8 
(10%) ≥3 months. There were 351 consultants reporting 
CMR, of whom 230 (66%) were cardiologists and 121 
(34%) radiologists; 81% of units offered a CMR service 
for patients with pacemakers and defibrillators.
Conclusions This survey provides a unique, 
contemporary insight into national CMR delivery 
with 100% centre engagement. The 10- year growth 
in CMR usage at fivefold has been remarkable but 
heterogeneous across the UK, with some regions still 
reporting low usage or long waiting times which may be 
of clinical concern.
INTRODUCTION
Cardiovascular magnetic resonance (CMR) is an 
advanced cross- sectional imaging technique and the 
reference standard for assessment of left ventricular 
(LV) and right ventricular (RV) volumes and func-
tion.1 It has a wide variety of clinical applications 
including coronary artery disease, cardiomyopathy, 
heart failure, aortopathy, valvular and congen-
ital heart disease.2 In international guidelines, the 
American College of Cardiology Appropriate Use 
Criteria Task Force, with other allied bodies, have 
deemed CMR as appropriate in the assessment of 
complex congenital heart disease,3 stable ischaemic 
heart disease,4 heart failure, cardiomyopathy, 
pericardial disease, cardiac masses, aortic disease, 
cardiac sarcoidosis and cardiac amyloidosis,5 and 
in more challenging cases of regurgitant valvular 
heart disease.6 In the European Society of Cardi-
ology guidelines on chronic coronary syndromes, 
non- invasive functional imaging including CMR 
stress perfusion has a class I indication in the initial 
diagnostic management of symptomatic patients 
with suspected and known coronary artery disease.7 
In heart failure guidelines, it has a class IIa indica-
tion for the assessment of dilated cardiomyopathy 
and a class I indication in patients with poor echo 
windows and in patients with certain suspected 
aetiologies of heart failure such as myocarditis, 
sarcoidosis and amyloidosis.8
Despite several class I and class II recommenda-
tions in the guidelines, there are wide variations 
nationally and internationally in terms of access to 
CMR, with availability remaining a major barrier 
to more widespread use of this technology. The 
funding of CMR in the UK is complex with different 
models in England, Northern Ireland, Scotland and 
Wales. Scanners may be purchased by the National 
Health Service (NHS) or private hospitals, or by 
universities, or with charitable funds, and within 
the NHS running costs may be reimbursed either by 
local or national commissioners of heathcare.
The British Society of CMR (BSCMR; www. 
bscmr. org) has periodically surveyed CMR units in 
the UK. Two previous surveys have been published 
in 2011 (2008–2010 data) and 2014 (2013 data; 
abstract only).9 10 The current survey sought to 
examine CMR growth over a 10- year time horizon, 
and to assess regional variation and other charac-
teristics of CMR units in the UK. A similar study 
has recently been performed looking at the provi-
sion of cardiac CT in the UK,11 as has a further 
study looking more generally at cardiac imaging 
provision.12
METHODS
Board members of the BSCMR identified all 
CMR units in the UK. In the case of England they 
reviewed all 223 NHS Trusts/hospitals to assess 
for the presence or absence of a CMR unit. In 
cases of doubt, further inquiries were made on 
the hospital’s website and by telephone with the 
cardiology and radiology departments. In Scot-
land, Ireland and Wales, where services are more 
centralised, direct approaches were made to CMR 
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practitioners in the region to identify all hospitals with a CMR 
unit. For all CMR units the service lead was identified. During 
2019, the CMR lead for each Trust was sent an electronic survey 
( www. sogosurvey. com) to capture key service delivery metrics, 
including clinical scan volumes for the previous 2 years (2017 
and 2018), and separately research scan volumes for 2018. The 
complete list of questions is provided in box 1. In cases of non- 
response, reminders were sent with follow- up emails and finally 
telephone calls. The population of each region within the UK 
was derived from publicly available data or from the Office for 
National Statistics.13 14 Statistics were performed in Microsoft 
Excel (Microsoft) and RStudio (RStudio, Boston, Massachu-
setts, USA). Continuous variables were assessed for normality 
via a histogram, and for skewed data variables are presented as 
median, IQR and range where illustrative. Data were analysed 
by region of the UK and compared with population statistics. 
Patient and public involvement was not deemed relevant to the 
design of the study, which was by its nature a survey.
RESULTS
Services and scanners
In 2019, there were 82 CMR units in the UK, and we achieved a 
100% response rate to the survey. Of these, 71 were in England, 
1 in Northern Ireland, 6 in Scotland and 4 in Wales. In the 2014 
survey there were 68 units, and in the 2011 survey (2008–2010 
data) 60 units, representing a 37% increase in CMR centres 
in the last decade. Thirty- seven units were in secondary care 
(district hospitals) and 45 in tertiary care/regional/academic 
centres. For every million people in the population, there were 
1.3 CMR units in England, 0.5 in Northern Ireland, 1.1 in Scot-
land and 1.3 in Wales.
The total number of MRI scanners used for CMR was 166 
(median 2/centre, IQR 1–3, range 1–5). Of those who provided 
manufacturer information, 107 (72%) were Siemens, 30 (20%) 
Philips, 9 (6%) General Electric and 2 (1%) others. In terms of 
field strength, 123 (81%) were 1.5 T, 27 (18%) 3 T and 1 other. 
The median age of magnets was 4 years, IQR 1-8, range new to 
15 years old; 17 (14%) magnets were 10 years old or older. The 
median age of CMR units was 10 years, IQR 6–14 years, range 
1–35 years.
In terms of scanner distribution, 139 were in England, 4 in 
Northern Ireland, 17 in Scotland and 6 in Wales. For every 
million people in the population, there were 2.5 CMR- enabled 
MRI scanners in England, 2.1 in Northern Ireland, 3.1 in Scot-
land and 1.9 in Wales. Within England this varied between 2.9 
scanners/million in both London and Northeast and Yorkshire 
regions, and 1.3 scanners/million in the East of England region.
Staffing
We identified 351 consultant physicians reporting CMR, of 
whom 230 (66%) were cardiologists and 121 (34%) radiolo-
gists. The median number of reporting consultants per unit was 
4, IQR 2–6, range 1–16. There were in addition 148 fellows, 
and 411 technologists involved in CMR services. Per million/
population the number of CMR consultants was 5.4 in England, 
5.3 in Northern Ireland, 4.2 in Scotland and 4.5 in Wales.
Volume
The total number of clinical CMR scans performed in the UK 
was 100 386 in 2017 and 114 967 in 2018, a 15% increase in 
1 year. In addition, there were 10 126 research scans performed 
in 2018. For comparison, in previous surveys the total annual 
number of scans in 2008 was 20 597, and in 2010 it was 38 
Box 1 Questions in the British Society of Cardiovascular 
Magnetic Resonance (BSCMR) 2019 survey
1. What is the name of your Trust?
2. What is the name of the CMR lead in your Trust?
3. What is the email of the CMR lead in your Trust?
4. Is your hospital district general/secondary care or academic/
tertiary care?
5. How many MRI scanners do you have that are used for 
CMR?
6. For each scanner please answer: manufacturer, age, field 
strength?
7. How is your clinical CMR service funded? (National Health 
Service England specialised commissioning/national tariff, 
Clinical Commissioning Group/local negotiation, other)?
8. Reporting
 – Number of CMR cardiology consultants reporting?
 – Number of CMR radiology consultants reporting?
 – Number of CMR fellows in dept?
 – Number of CMR techs in dept?
9. Clinical indication (%)
 – Heart failure
 – Cardiomyopathy
 – Function and viability
 – Stress perfusion
 – Acquired vascular disease
 – Valvular heart disease
 – Myocarditis
 – Pericardial disease
 – Paediatric and congenital heart disease
 – Cardiac transplantation/others (eg. masses).
10. Service delivery
 – What year did CMR start?
 – How many clinical CMR scans performed in 2018?
 – How many clinical CMR scans performed in 2017?
 – How many half day CMR sessions per week total across all 
scanners?
 – How many patients per half day session?
 – Mean inpatient waiting time? (days)
 – Mean outpatient waiting time? (days)
11. Do you have a programme for pacemaker/device patients?
12. If you have a programme for pacemaker/device patients, do 
you only scan conditional devices or also non- conditional 
devices?
13. Do you have general anaesthetic lists?
14. Do you have an interventional CMR programme?
15. Do you have access to T1 mapping?
16. Do you have a quality assurance programme in place?
17. Do you have a regular CMR meeting?
18. Do you have an audit programme?
19. Are you part of a hub- and- spoke model?
20. Training
 – How many trainees are there in your department?
 – Which level is training offered to? (1/2/3)
 – How many level 3 accredited trainers are there in your 
department?
21. Is research performed in your department?
22. Is there external, peer- reviewed research grant funding 
contributing to research in your department (during past 12 
months)?
23. How many research CMR scans in 2018?
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485, although the response rate in these surveys did not achieve 
100%. This therefore represents an estimated fivefold growth 
in 10 years.
In 2018, the median number of scans/centre was 780, IQR 
373–1951, range 98–10 000. In 2017, these data were median 
750, IQR 374–1600, range 100–7500 based on 80 centres, 
as two services started in 2018. For comparison, in 2008 the 
median number of scans was 240.
By head of UK population in 2018, there were 1731 scans/
million people. Table 1 shows these data by region. The number 
of scans/million population were 1907 scans in England, 1302 in 
Northern Ireland, 827 in Scotland and 396 in Wales. In England, 
this varied between 4256 scans/million in the London region and 
985 scans/million in the Southeast region (figure 1A).
A significant part of the growth has been in the numbers of 
scans performed in each centre as well as an increase in the 
number of centres. Data for annual scan volume by centre are 
shown in table 2 and figure 2A with data from 2013 for compar-
ison. Three very high- volume centres performed >5000 scans/
year.
Waiting times
Centres reported their mean outpatient referral to diagnostic 
(RTD) scan time. The median RTD was 41 days, IQR 30–49 days, 
range 5–180 days. Twenty- five (30%) centres had a mean RTD 
longer than 42 days (6 weeks), and 8 (10%) had a mean RTD 
of 90 days or more. The median reported RTD was 40 days in 
England, 180 days in Northern Ireland, 55 days in Scotland and 
50 days in Wales. By region in England, the median reported 
RTD ranged from 25 days in London to 44 days in the South-
west region (table 1, figures 1B and 2B). The median reported 
inpatient RTD was 3 days, IQR 2–4 days, range 0–7 days.
Indications
The mean percentage for each indication for CMR was heart 
failure 21%, cardiomyopathy 27%, function and viability 22%, 
stress perfusion 24%, acquired vascular disease 6%, valvular 
heart disease 5%, myocarditis/pericardial disease 10%, paedi-
atric/congenital heart disease 10%, cardiac transplant 0.4%, 
others, for example, cardiac masses 3%. This adds up to >100% 
likely indicating some overlap between indications. Of 70 
centres answering a question about the performance of stress 
perfusion CMR, 58 (83%) indicated that they had a stress perfu-
sion service.
Quality/Research/Training
Of the 74 units answering questions on clinical governance, 
66 (89%) had a formal quality assurance (QA) programme, 
63 (85%) had a regular CMR clinical meeting and 58 (78%) 
had a regular audit programme. Forty- four (59%) of 74 units 
were active in research. Of these units, the median number of 
research scans was 100/year, IQR 30–377, range 2–1600. Fifty- 
three (72%) of 74 units had cardiology/radiology trainees, mean 
number per unit 3.4, range 1–25. Thirty- seven (23%) units were 
offering training up to level 3 and a further 15 (20%) to level 2.
Other aspects of CMR service
Seventy- four units provided data on whether they had a service 
for patients with cardiac implanted electronic devices (pace-
makers and defibrillators). Of these, 60 (81%) provided this 
service; 20 (33%) were scanning both MRI conditional and non- 
conditional devices, with 40 (67%) scanning MRI conditional 
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for patients with cardiac implanted electronic devices included 5 
tertiary referral centres. Finally, 54 of 73 units (74%) had access 
to T1 mapping, 18 of 72 units (25%) had general anaesthetic 
(GA) cardiac lists and 3 of 74 units (4%) had an interventional 
CMR programme.
DISCUSSION
The current BSCMR survey is the first to reach a 100% response 
rate across the UK. We therefore have a unique and valuable 
insight into the ‘real- world’ state of UK CMR service delivery, 
not currently available in any other government or NHS dataset. 
The 100% response rate is itself remarkable and a testament to 
the engagement of physicians active in CMR in the UK with a 
representative professional society (BSCMR).
The three iterations of the BSCMR survey have shown a remark-
able growth in the use of CMR at approximately fivefold over the 
last 10 years, although this will to a degree be an overestimate as 
previous surveys did not achieve a 100% response rate. There is 
unfortunately a paucity of datasets from other countries with which 
to compare our results. There are publicly available data from the 
US Medicare system, which showed that in 2017 there were 26 796 
CMR scans performed on Medicare beneficiaries, compared with 
102 886 scans in the UK.15 Although Medicare only covers 17.8% of 
Figure 1 (A) Map showing number of cardiovascular magnetic resonance (CMR) scans per million population by UK region in 2018. (B) Map 
showing median outpatient waiting time for CMR by UK region (days).
Table 2 Number (%) of CMR units by scan volume
Number of CMR centres and their annual scan volumes/year
Year No data <300 300–500 501–1000 >1000
2018 0 7 (9%) 20 (24%) 23 (28%) 32 (39%)
2013 5 (9%) 9 (16%) 14 (25%) 7 (13%) 20 (36%)
CMR, cardiovascular magnetic resonance.
Figure 2 (A) Number of scans by cardiovascular magnetic resonance 
(CMR) unit in 2018 (black bars). Data for 2013 are shown in blue for 
comparison. The units are ranked by volume for each year with no 
linkage between 2013 and 2018 data. (B) Outpatient waiting times for 
CMR by unit (days).
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the population of the USA, beneficiaries are in general aged over 65 
years where the burden of cardiovascular disease is greatest. Given 
that the population of the USA is 329 000 000,16 17.8% of the 
population represents ~58 562 000, giving a rate of CMR among 
Medicare beneficiaries of ~406 scans/million; the comparator for 
the UK in 2017 was 1511, 3.7 times higher. The EuroCMR registry 
collected data on 27 781 scans from 57 sites in 15 countries between 
2007 and 201217 and the Society for Cardiovascular Magnetic Reso-
nance has sponsored the Global CMR Registry project which has 
collected data from 62 456 scans between 2013 and 2017 from 10 
centres.18 While these are both registries looking at indications and 
clinical outcomes rather than scan volumes, it is clear that viewed 
internationally, the UK CMR activity levels are numerically large. 
There are significant benefits to patients from the widespread use of 
this imaging modality in terms of more sophisticated phenotyping, 
for example, non- invasive rather than invasive assessment for the 
aetiology of heart failure is both more clinically effective and also 
safer.19
However, growth has not been uniform across the UK, with wide 
disparities in use of and access to CMR. The annual CMR volume 
per unit varies widely from 98 to 10 000 patients. The BSCMR 
previously recommended a minimum number of scans per centre per 
year of 300, but some low volume centres may be in their first year 
of CMR practice.20 In terms of CMR activity by million population 
for the year 2018, this varied from a low of 396 in Wales to a high 
of 4256 in London, a greater than 10- fold difference. Data anal-
ysis by region may be affected by patients being sent across regional 
boundaries for CMR, but this also highlights low access to CMR 
in their home region. However, we should note that CMR services 
in London include supra- regional and national services such as the 
National Amyloid Centre, and specialised units for thalassaemia, 
three centres for paediatric and adult congenital heart disease and 
a service for non- conditional cardiac devices, and this will lead to 
apparent higher activity levels in the London region per million 
population.
In 2010, the BSCMR and British Society of Cardiovascular 
Imaging estimated CMR activity would need to be ~2275 scans per 
million adults per year.20 While 10 years later it is likely that the 
need will have increased, our data show that this target has been 
achieved in London but not in any other region of the UK. It is inter-
esting to speculate why there is such a variation in activity across the 
UK. The most likely explanation is that cardiologists with signifi-
cant experience of CMR are aware of its utility and have a lower 
threshold for referral than those with more limited exposure. A 
second possibility is that in some areas long waiting times are a disin-
centive to refer for CMR. A third possibility is that some areas have 
very well- established nuclear medicine services and that this is used 
in preference to CMR for ischaemia and viability assessment, despite 
the fact that CMR has been shown to have greater diagnostic accu-
racy,21 22 prognostic ability23 and is more cost- effective from an NHS 
perspective,24 25 although the rapid expansion in cardiac CT services 
has further complicated the picture. However, where CMR activity 
rates are low, it is likely that patients are being managed without the 
potential benefits and insights of this advanced cardiac imaging tech-
nology, not just in coronary artery disease, but across the full range 
of CMR indications.2 This disparity in access to CMR is one of the 
main findings of this survey.
Clinical volume is an important measure of access to CMR, but so 
too are waiting times. This survey shows that the median of the mean 
reported outpatient waiting times for CMR was 25 days in London 
and 180 days in Northern Ireland, a sevenfold difference. Given that 
this is a mean some patients may be waiting significantly longer. For 
coronary artery disease or cardiomyopathy, for instance, a 6- month 
wait may be clinically meaningful if decisions about revascularisation 
or device implantation are being based on the results of CMR exams, 
so this variation in waiting time may be a clinical concern.
The limitations of this survey are that the data are self- reported 
and therefore may not be completely accurate, but a strength is the 
engagement of all UK CMR centres. Small volume private CMR 
units may not have been captured by this survey, but private scans 
performed in NHS units have been. Waiting time data may not 
reflect planned interval scans. Finally as this is a survey we do not 
present outcome data.
Overall, our data indicate a lack of equitable access to CMR across 
the UK. Where there is clear evidence of resource under- provision, 
action is needed by healthcare providers, the NHS and government, 
bearing in mind the complex funding arrangements for CMR in the 
UK. High levels of regional variation in access to CMR are unaccept-
able given its strong evidence base and the high- level recommenda-
tions for its use in international clinical care guidelines.
CONCLUSIONS
This survey provides a unique, contemporary, ‘real- world’ insight 
into a national CMR service delivery model with 100% centre 
engagement. The 10- year growth in CMR usage at approximately 
fivefold has been remarkable but heterogeneous across the UK, with 
some regions still reporting low usage or long waiting times which 
may be of clinical concern.
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